These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 35993)

  • 1. Suicidal risk in the treatment of outpatient schizophrenics with long-acting neuroleptics.
    Niturad A; Nicholschi-Oproiu L
    Agressologie; 1978; 19(C):145-8. PubMed ID: 35993
    [No Abstract]   [Full Text] [Related]  

  • 2. [Prophylactic efficacy of long-acting vs. short-acting neuroleptics in schizophrenic out-patients (author's transl)].
    Tegeler J; Lehmann E; Stockschlaeder M
    Nervenarzt; 1980 Nov; 51(11):654-61. PubMed ID: 6109262
    [No Abstract]   [Full Text] [Related]  

  • 3. [Depot neuroleptics in social psychiatric practice].
    Pruss U; Rose HK; Zechner A
    Psychiatr Prax; 1984 Jul; 11(4):101-8. PubMed ID: 6148764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Considerations on the use of long-acting neuroleptics in a mental health center].
    Carotti P; Merli R
    Minerva Med; 1986 Sep; 77(34-35):1577-83. PubMed ID: 2876402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Experience with long acting psychopharmaceutics in psychiatric hospitals].
    Reimer F
    Int Pharmacopsychiatry; 1974; 9(4):245-7. PubMed ID: 4156352
    [No Abstract]   [Full Text] [Related]  

  • 6. Eleven years of experience with depot neuroleptics.
    Gross H; Kaltenbäck E; Pfolz H
    Acta Psychiatr Belg; 1981; 81(2):128-32. PubMed ID: 6117183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The psychoprophylactic importance of treatment with depot neuroleptics in schizophrenia].
    Chiriţă V; Stanciu J; Pirozynski T
    Rev Med Chir Soc Med Nat Iasi; 1989; 93(3):497-500. PubMed ID: 2576888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experience with depot neuroleptics in ambulatory practice.
    Fiolet J
    Acta Psychiatr Belg; 1981; 81(2):182-8. PubMed ID: 6117188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Role of long-acting neuroleptics in the treatment of schizophrenia].
    Levine J; Schooler NR; Cassano G
    Encephale; 1979; 5(3):285-90. PubMed ID: 39740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advantages and disadvantages of depot-neuroleptics as maintenance medication for chronic schizophrenics.
    Möller HJ; Kissling W
    Clin Neuropharmacol; 1986; 9 Suppl 4():259-62. PubMed ID: 2882841
    [No Abstract]   [Full Text] [Related]  

  • 11. An atypical long-acting injectable antipsychotic: implications for pharmacotherapy of schizophrenia.
    Dursun S
    J Psychopharmacol; 2005 Sep; 19(5 Suppl):3-4. PubMed ID: 16144780
    [No Abstract]   [Full Text] [Related]  

  • 12. [Experiences with depot-neuroleptics in an after-care unit. Organization of the therapy exemplified with pipotiazine palmitate].
    Salvesen C; Vaksdal K
    Tidsskr Nor Laegeforen; 1973 Aug; 93(24):1699-703. PubMed ID: 4149082
    [No Abstract]   [Full Text] [Related]  

  • 13. [5 years' experience with prolonged-action neuroleptics].
    Lopez-Ibor Aliño JM; Tabares Pujante J
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1973; 1(5):721-31. PubMed ID: 4150175
    [No Abstract]   [Full Text] [Related]  

  • 14. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
    Lindenmayer JP; Eerdekens E; Berry SA; Eerdekens M
    J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Long-term treatment of outpatients with depot neuroleptics (author's transl)].
    Saameli W
    Schweiz Rundsch Med Prax; 1981 Feb; 70(6):206-10. PubMed ID: 6113584
    [No Abstract]   [Full Text] [Related]  

  • 16. Depot neuroleptics: side effects and safety.
    Marder SR
    J Clin Psychopharmacol; 1986 Feb; 6(1 Suppl):24S-29S. PubMed ID: 2870089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical experience with pipothiazine palmitate (19552 R.P.) in hospitalized and open ward patients with functional psychoses.
    Salvesen C; Vaksdal K
    Behav Neuropsychiatry; 1973 Oct-1974 Mar; 5(7-12):3-7. PubMed ID: 4154740
    [No Abstract]   [Full Text] [Related]  

  • 18. Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies.
    Kane JM
    J Clin Psychiatry; 2003; 64 Suppl 16():34-40. PubMed ID: 14680417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The first long-acting atypical antipsychotic: new milestone in the treatment of schizophrenia].
    Faludi G
    Neuropsychopharmacol Hung; 2005 Mar; 7(1):22-7. PubMed ID: 16167464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The risk of rehospitalisation during therapy with atypical and typical neuroleptics--a contribution to differential indication].
    Müller P; Nerenz H; Schaefer E
    Psychiatr Prax; 2002 Oct; 29(7):388-91. PubMed ID: 12378421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.